China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults
Retrieved on:
Monday, May 18, 2020
Health, Pharmaceutical, Branches of biology, Organ systems, Nervous system, Neurological disorders, Amphetamine, Huntington's disease, Tardive dyskinesia, Neurotransmitter transporters, Deutetrabenazine, Teva Pharmaceutical Industries, Vesicular monoamine transporter, Movement disorders, Huntington's Disease, Tardive Dyskinesia, AUSTEDO® (deutetrabenazine), Teva
This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.
Key Points:
- This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.
- The approval of AUSTEDO in China is an exciting milestone for Teva," said Gianfranco Nazzi, Executive Vice President, International Markets, at Teva.
- Tardive dyskinesia is a movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, trunk and extremities.
- AUSTEDO is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntingtons disease.